Developing software to analyze and predict antibody structures and targets.
Official title: Software for the complete characterization of antibody repertoires: from germline and mRNA sequence assembly to deep learning predictions of their protein structures and targets
Funded at Dnastar, INC. · NIH-10915664 · Data updated 2026-11-12
This study is working on new software that helps understand the different antibodies your body makes when fighting infections or getting vaccinated, which could lead to better treatments and personalized care for conditions like autoimmune diseases.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dnastar, INC. NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 29, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $681,914 |
| NIH project number | 5R44GM150362-02 |
| Project ID | NIH-10915664 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with autoimmune diseases or those undergoing treatment for infections where antibody response is critical.
✕Less likely to help
Patients who do not have autoimmune diseases or are not affected by conditions related to antibody responses may not benefit from this research.
What this research studies
This research focuses on creating advanced software that can fully characterize the diverse range of antibodies produced by B cells in response to infections, vaccinations, and diseases. By utilizing techniques such as DNA/RNA sequencing and deep learning, the project aims to assemble and analyze the genetic sequences of antibodies, predicting their structures and potential targets. This could lead to better understanding and treatment of various conditions, including autoimmune diseases and infections. Patients may benefit from improved diagnostics and personalized therapies based on their unique antibody profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and diagnostics for patients with autoimmune diseases and other conditions related to antibody responses.
How similar studies have gone: Other research has shown promise in using advanced sequencing and computational methods to analyze antibody repertoires, indicating that this approach has potential for success.
Where this research is happening
-
Dnastar, INC.
Madison, United States Active
Researchers
- Principal investigator: Durfee, Timothy J — Dnastar, INC.
- Study coordinator: Durfee, Timothy J
Related research
Other NIH-funded projects on the same topics.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Predicting how antimalarial drug resistance spreads with AI
A powerful AI model will be built to forecast how resistance to antimalarial drugs might spread in Africa and beyond, helping clinicians and public health teams stay ahead of outbreaks.
-
Self-supervised deep learning for biological sequences
A deep learning project uses self-supervised methods to better understand biological sequences and related data, with the goal of advancing biology and medicine.
-
Mobile phone imaging and AI to screen oral cancers in low-resource settings
A low-cost mobile phone device with artificial intelligence is being developed to help frontline health workers screen for oral cancer early in low-resource areas.
-
Linking Genetic Variants to Real-Life Health Effects with Smart AI
A new AI-powered approach will predict how genetic differences affect health across multiple levels to help doctors understand diseases and tailor care.
-
Integrative AI tools to map protein sequences to structures and functions
A scientist team will develop advanced AI methods to better connect protein sequences, their 3D shapes, and how they work, using large biological data from sequencing and structures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.